Olanzapine within steroid-sparing antiemetic regimen to prevent chemotherapy-induced nausea and vomiting in patients with acute leukemia receiving multi-day intensive chemotherapy

A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)

(2022) Yuanyuan Zhao et al.   EClinicalMedicine

Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis

(2021) Ronald Chow et al.   SUPPORTIVE CARE IN CANCER

The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis

(2021) Dong-Yang Wang et al.   Frontiers in Oncology

Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia

(2020) Ciera L. Patzke et al.   Journal of Clinical Medicine

Antiemetic prophylaxis for induction chemotherapy in patients with acute myeloid leukemia

(2020) Jessie Signorelli et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213

(2019) Hannah Woopen et al.   SUPPORTIVE CARE IN CANCER

Olanzapine as a rescue antiemetic in hematopoietic stem cell transplant

(2019) Taylor Monson et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Hironobu Hashimoto et al.   LANCET ONCOLOGY

Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial

(2018) Amber B. Clemmons et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

CINV: still troubling patients after all these years

(2018) Matti Aapro   SUPPORTIVE CARE IN CANCER

Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management

(2017) Bernardo L. Rapoport   Frontiers in Pharmacology

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

(2016) Rudolph M. Navari et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation

(2016) Midori Nakagaki et al.   SUPPORTIVE CARE IN CANCER

The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

(2013) Rudolph M. Navari et al.   SUPPORTIVE CARE IN CANCER

Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting

(2009) Lijun Tan et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH